Skip to main content
. 2002 Dec;51(6):864–869. doi: 10.1136/gut.51.6.864

Table 2.

Results of retreatment according to baseline features and regimens administered

End of treatment response Sustained response
Biochemical (% (No)) Complete (% (No)) Biochemical (% (No)) Complete (% (No))
All patients 46.6 (271/581) 38.7 (206/532) 18.7 (109/581) 15.7 (88/559)
Cirrhosis
    Present 29.6 (19/64) 27.5 (16/58) 14 (9/64) 12.5 (8/64)
    Absent 48.7 (252/517) 40 (180/474) 19.3 (100/517) 16.1 (80/495)
    p Value 0.004 0.065 0.30 0.44
Genotype
    1 45.6 (142/311) 30.4 (92/302) 15.1 (47/311) 14.4 (43/297)
    Non-1 47.7 (129/270) 49.5 (114/230) 22.9 (62/270) 17.1 (45/262)
    p Value 0.60 0.001 0.016 0.38
HCV-RNA
    ≥2×106 copies/ml 30.8 (21/68) 30 (18/60) 22 (15/68) 17.6 (12/68)
    <2×106 copies/ml 49.5 (169/341) 37.3 (115/308) 18.1 (62/341) 16.3 (55/336)
    p Value 0.005 0.27 0.45 0.79
IFN retreatment regimens
    Standard dose (234 MU) 39.2 (33/84) 31.6 (25/79) 8.3 (7/84) 6.1 (5/82)
    Medium dose (>234–468 MU) 46.3 (133/287) 34 (91/267) 15.3 (44/287) 13.2 (36/272)
    High dose (>468 MU) 50 (105/210) 48.3 (90/186) 27.6 (58/210) 22.9 (47/205)
    p Value 0.24 0.003 0.001 0.001
Length of retreatment
    6 months 44 (99/225) 41.2 (83/201) 11.1 (25/225) 10.1 (21/208)
    12 months 48.3 (172/356) 58.3 (193/331) 23.6 (84/356) 19 (67/351)
    p Value 0.31 0.001 0.001 0.005
1st→2nd IFN course
    Standard→standard 38.4 (20/52) 39.5 (19/48) 13.4 (7/52) 9.6 (5/52)
    Standard→medium/high 49.5 (164/331) 39.5 (121/306) 21.7 (72/331) 17.2 (55/319)
    Medium/high→standard 40.6 (13/32) 19.3 (6/31) 0 (0/32) 0 (0/30)
    Medium/high→medium/high 44.5 (74/166) 40.8 (60/147) 18 (30/166) 17.7 (28/158)
    p Value 0.35 0.15 0.016 0.044
Type of IFN for retreatment
    Recombinant α2b 46.7 (256/548) 52.3 (261/499) 18.8 (103/548) 15.5 (82/526)
    Leucocytic αN-3 45.4 (15/33) 45.4 (15/33) 18.1 (6/33) 18.1 (6/33)
    p Value 0.88 0.44 0.93 0.69

HCV, hepatitis C virus; IFN, α interferon; MU, mega units.